Immutep Ltd (IMM) reported that it will provide an update on the ongoing TACTI-mel Phase I clinical trial and the clinical development of eftilagimod alpha (“efti” or “IMP321”) in a global webcast, including a Q&A session
http://crweworld.com/article/news-provided-by-globenewswire/1031729/immutep-to-host-eftilagimod-alpha-clinical-development-update-global-webcast
Ann: Webcast details for update on eftilagimod alpha (IMP321), page-6
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.3¢ |
Change
0.018(6.14%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.5¢ | 29.0¢ | $565.0K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 344870 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 237922 | 27 |
View Market Depth
| Last trade - 14.18pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
